Gender Differences in Discontinuation of Antiretroviral Treatment Regimens

Abstract

Background Reported reasons for change or discontinuation of antiretroviral therapy (δART) include adverse events, intolerability and non-adherence. Little is known how reasons for δART differ by gender. Methods In a retrospective cohort study, rates and reasons for δART alterations in a large University-based HIV clinic cohort were evaluated. Logistic regression analyses were used to evaluate the relationship between reasons for δART and gender. Cox proportional hazard models were used to investigate time to δART. Results In total 631 HIV+ individuals were analyzed. Women (n=164) and men (n=467) were equally likely (53.0% and 54.4%, respectively) to discontinue treatment within 12 month of initiating a new regimen. Reasons for δART, however, were different based on gender - women were more likely to δART due to poor adherence (adj.OR, 1.44; 95% CI: 0.85-2.42), dermatologic symptoms (adj.OR, 2.88; 95% CI: 1.01-8.18), neurological reasons (adj.OR, 1.82; 95% CI: 0.98-3.39), constitutional symptoms (adj. OR, 2.23; 95% CI: 1.10-4.51) and concurrent medical conditions (adj.OR, 2.03; 95% CI: 1.00-4.12). Conclusions Although the rates of δART are similar among men and women in clinical practice, the reasons for treatment changes are different based on gender. The potential for unique patterns of adverse events and poor adherence among women requires further investigation.

Incidences and risk factors of first-line HAART discontinuation: a limitation to the success of the “seek, test, treat, and retain” strategy?

“…Contrary to certain studies (Kempf et al, 2009), but in agreement with others (Barber et al, 2011), women discontinued their first HAART more than men. This increased risk was observed for discontinuations due to intolerance and simplification, but not for discontinuation due to failure.…”

Recruitment and Retention of Diverse Populations in Antiretroviral Clinical Trials: Practical Applications from the Gender, Race And Clinical Experience Study

“…2504 treatment-naïve women enrolled into clinical trials has been steadily increasing, recruitment and retention of treatmentexperienced women in trials have been less successful. 4,9,12 Clinical trials that are specifically designed to recruit and retain a sufficient number of HIV-infected women will ensure that studies are adequately powered for between-sex comparisons and provide meaningful data on the effects of ARVs in women.…”

Safety, Tolerability, and Efficacy of Raltegravir in a Diverse Cohort of HIV-Infected Patients: 48-Week Results from the REALMRK Study

“…A trend for higher discontinuation rates in women due to adverse events has been noted with other antiretroviral agents. 23,38,39 Raltegravirbased regimens were well tolerated by patients who were intolerant of their prior ART: 81% of these patients completed the study, and only 2% withdrew because of adverse events.…”